Cargando…

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies

Hepatocellular carcinoma is the fourth leading cause of cancer-related death worldwide. Depending on the extent of disease and competing comorbidities for mortality, multiple liver-directed therapy options exist for the treatment of hepatocellular carcinoma. Advancements in radiation oncology have l...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaub, Stephanie K., Hartvigson, Pehr E., Lock, Michael I., Høyer, Morten, Brunner, Thomas B., Cardenes, Higinia R., Dawson, Laura A., Kim, Edward Y., Mayr, Nina A., Lo, Simon S., Apisarnthanarax, Smith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071169/
https://www.ncbi.nlm.nih.gov/pubmed/30068240
http://dx.doi.org/10.1177/1533033818790217
_version_ 1783343823324184576
author Schaub, Stephanie K.
Hartvigson, Pehr E.
Lock, Michael I.
Høyer, Morten
Brunner, Thomas B.
Cardenes, Higinia R.
Dawson, Laura A.
Kim, Edward Y.
Mayr, Nina A.
Lo, Simon S.
Apisarnthanarax, Smith
author_facet Schaub, Stephanie K.
Hartvigson, Pehr E.
Lock, Michael I.
Høyer, Morten
Brunner, Thomas B.
Cardenes, Higinia R.
Dawson, Laura A.
Kim, Edward Y.
Mayr, Nina A.
Lo, Simon S.
Apisarnthanarax, Smith
author_sort Schaub, Stephanie K.
collection PubMed
description Hepatocellular carcinoma is the fourth leading cause of cancer-related death worldwide. Depending on the extent of disease and competing comorbidities for mortality, multiple liver-directed therapy options exist for the treatment of hepatocellular carcinoma. Advancements in radiation oncology have led to the emergence of stereotactic body radiation therapy as a promising liver-directed therapy, which delivers high doses of radiation with a steep dose gradient to maximize local tumor control and minimize radiation-induced treatment toxicity. In this study, we review the current clinical data as well as the unresolved issues and controversies regarding stereotactic body radiation therapy for hepatocellular carcinoma: (1) Is there a radiation dose–response relationship with hepatocellular carcinoma? (2) What are the optimal dosimetric predictors of radiation-induced liver disease, and do they differ for patients with varying liver function? (3) How do we assess treatment response on imaging? (4) How does stereotactic body radiation therapy compare to other liver-directed therapy modalities, including proton beam therapy? Based on the current literature discussed, this review highlights future possible research and clinical directions.
format Online
Article
Text
id pubmed-6071169
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60711692018-08-06 Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies Schaub, Stephanie K. Hartvigson, Pehr E. Lock, Michael I. Høyer, Morten Brunner, Thomas B. Cardenes, Higinia R. Dawson, Laura A. Kim, Edward Y. Mayr, Nina A. Lo, Simon S. Apisarnthanarax, Smith Technol Cancer Res Treat Review Hepatocellular carcinoma is the fourth leading cause of cancer-related death worldwide. Depending on the extent of disease and competing comorbidities for mortality, multiple liver-directed therapy options exist for the treatment of hepatocellular carcinoma. Advancements in radiation oncology have led to the emergence of stereotactic body radiation therapy as a promising liver-directed therapy, which delivers high doses of radiation with a steep dose gradient to maximize local tumor control and minimize radiation-induced treatment toxicity. In this study, we review the current clinical data as well as the unresolved issues and controversies regarding stereotactic body radiation therapy for hepatocellular carcinoma: (1) Is there a radiation dose–response relationship with hepatocellular carcinoma? (2) What are the optimal dosimetric predictors of radiation-induced liver disease, and do they differ for patients with varying liver function? (3) How do we assess treatment response on imaging? (4) How does stereotactic body radiation therapy compare to other liver-directed therapy modalities, including proton beam therapy? Based on the current literature discussed, this review highlights future possible research and clinical directions. SAGE Publications 2018-08-01 /pmc/articles/PMC6071169/ /pubmed/30068240 http://dx.doi.org/10.1177/1533033818790217 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Schaub, Stephanie K.
Hartvigson, Pehr E.
Lock, Michael I.
Høyer, Morten
Brunner, Thomas B.
Cardenes, Higinia R.
Dawson, Laura A.
Kim, Edward Y.
Mayr, Nina A.
Lo, Simon S.
Apisarnthanarax, Smith
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies
title Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies
title_full Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies
title_fullStr Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies
title_full_unstemmed Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies
title_short Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies
title_sort stereotactic body radiation therapy for hepatocellular carcinoma: current trends and controversies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071169/
https://www.ncbi.nlm.nih.gov/pubmed/30068240
http://dx.doi.org/10.1177/1533033818790217
work_keys_str_mv AT schaubstephaniek stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies
AT hartvigsonpehre stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies
AT lockmichaeli stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies
AT høyermorten stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies
AT brunnerthomasb stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies
AT cardeneshiginiar stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies
AT dawsonlauraa stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies
AT kimedwardy stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies
AT mayrninaa stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies
AT losimons stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies
AT apisarnthanaraxsmith stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies